#ASCO22 – RCT: Upfront modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan plus Panitumumab vs. Fluorouracil, Leucovorin, and Oxaliplatin plus Panitumumab for patients with RAS/BRAF wild-type metastatic colorectal cancer.
7 Jun, 2022 | 10:49h | UTC